الصفحة الرئيسية>>Signaling Pathways>> DNA Damage/DNA Repair>> DNA/RNA Synthesis>>CTP Synthetase-IN-1

CTP Synthetase-IN-1

رقم الكتالوجGC71196

يعتبر CTP Synthetase-IN-1 مثبط سيتيدين 5'-ثلاثي الفوسفات (CTPS) الفعال عن طريق الفم مع IC50s من 32 نانومتر و 18 نانومتر بالنسبة للبشر CTPS1 و CTPS2 على التوالي.

Products are for research use only. Not for human use. We do not sell to patients.

CTP Synthetase-IN-1 التركيب الكيميائي

Cas No.: 2338811-71-3

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
188٫00
متوفر
5 mg
167٫00
متوفر
10 mg
279٫00
متوفر
25 mg
576٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
CTP Synthetase-IN-1 is a potent, orally active cytidine 5'-triphosphate synthetase (CTPS) inhibitor with IC50s of 32 nM and 18 nM for human CTPS1 and human CTPS2, respectively. CTP Synthetase-IN-1 has anti-inflammatory effects.

CTP Synthetase-IN-1 (compound 27) inhibits rat CTPS1, rat CTPS2, mouse CTPS1, and mouse CTPS2 with IC50 values of 27 nM, 23 nM, 26 nM, and 33 nM, respectively[1].

CTP Synthetase-IN-1 (compound 27; 10-50 mg/kg; p.o; twice daily; for 18 days) shows significant pharmacological responses in collagen-induced arthritis (CIA) model[1].

References:
[1]. Andrew Novak, et al. Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation. J Med Chem. 2022 Dec 22;65(24):16640-16650.

مراجعات

Review for CTP Synthetase-IN-1

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CTP Synthetase-IN-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.